USPTO Examiner COOK LISA V - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18727602BIOMARKER FOR PREDICTING THE PROGNOSIS OF COLORECTAL CANCERFebruary 2025December 2025Allow1711NoNo
18898854Antibodies Targeting ActRIIA and ActRIIBSeptember 2024December 2024Abandon300NoNo
18890453ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATIONSeptember 2024March 2025Allow610YesNo
18765553CANCER VACCINES TARGETING SURVIVIN AND USES THEREOFJuly 2024March 2026Allow2011NoNo
18652576ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOFMay 2024January 2026Abandon2001NoNo
18644619SYSTEM AND SENSOR ARRAYApril 2024February 2025Allow1012NoNo
18624620BIOMARKERS FOR PANCREATIC CANCERApril 2024February 2026Allow2310NoNo
18417299ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOFJanuary 2024June 2024Allow511YesNo
18537241Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-MyristoyltransferaseDecember 2023January 2026Allow2510NoNo
185246133E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer modelNovember 2023March 2025Allow1610NoNo
18523859IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICSNovember 2023May 2025Allow1810NoNo
18507167ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOFNovember 2023July 2025Allow2021NoNo
18372933DEVICE AND METHOD FOR DETECTION OF ANALYTESSeptember 2023December 2024Allow1510NoNo
18460254METHODS AND DEVICES FOR ASSAYING A BIOLOGICAL SAMPLESeptember 2023July 2024Allow1041YesNo
18460221SYSTEM AND SENSOR ARRAYSeptember 2023March 2024Allow610YesNo
18357013CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSJuly 2023June 2024Allow1111YesNo
18356985CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSJuly 2023June 2025Allow2300YesNo
18348398Early and Non Invasive Method for Assessing a Subject's Risk of Having Pancreatic Ductal Adenocarcinoma and Methods of Treatement of Such DiseaseJuly 2023July 2024Allow1200NoNo
18344721ANTIBODIES THAT BIND TO AXL PROTEINSJune 2023October 2025Allow2711NoNo
18344726ANTIBODIES THAT BIND TO AXL PROTEINSJune 2023October 2025Allow2811NoNo
18205581METHOD FOR FLUORESCENT IMMUNOASSAY (FIA) AND CHEMILUMINESCENT IMMUNOASSAY (CLIA) BASED ON ELECTROKINETIC ACCELERATIONJune 2023October 2023Allow400NoNo
18329252IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING APPARATUS AND METHODJune 2023March 2025Allow2210NoNo
18295739SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULESApril 2023February 2025Abandon2310NoNo
18182211CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTORMarch 2023January 2025Allow2310NoNo
18044172Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-MyristoyltransferaseMarch 2023September 2023Allow600NoNo
18176283Tumor Antigens for Determining Cancer TherapyFebruary 2023April 2025Allow2611NoNo
17984197MARKERS OF ENDOMETRIAL CANCERNovember 2022September 2025Abandon3411NoNo
18053273ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATIONNovember 2022March 2025Allow2810NoNo
17952919CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYSeptember 2022July 2023Allow931NoNo
17931919DETERMINATION OF NFKB PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENESSeptember 2022January 2026Abandon4010NoNo
17906273METHOD FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A CANCERSeptember 2022June 2025Allow3300NoNo
17930143ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOFSeptember 2022August 2023Allow1111NoNo
17855000MULTIFUNCTIONAL BEADS AND METHODS OF USE FOR CAPTURING CELLSJune 2022March 2025Allow3220YesNo
17808420Early Detection Of Hepatocellular CarcinomaJune 2022May 2025Abandon3411NoNo
17787868OVARIAN CANCER BIOMARKER DETECTION THROUGH OVARIAN BLOOD SAMPLINGJune 2022January 2026Allow4310NoNo
17839262AMYLOID BETA DETECTION BY MASS SPECTROMETRYJune 2022July 2024Allow2620YesNo
17748522METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING, GERMLINE MISMATCH REPAIR DEFICIENCIES, LYNCH SYNDROME AND ASSESSING GERMLINE RISKS OF CANCERMay 2022March 2024Allow2241YesNo
17777599NOVEL POCT DIAGNOSTIC SYSTEM FOR CANCERMay 2022December 2025Abandon4301NoNo
17743995CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSMay 2022May 2023Allow1212YesNo
17743961CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSMay 2022May 2023Allow1212YesNo
17739274CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYMay 2022October 2022Allow620YesNo
17739278CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYMay 2022February 2023Allow920NoNo
17731833Tissue-Derived Extracellular Vesicles and Their Use as DiagnosticsApril 2022January 2026Allow4530YesNo
17720067METHODS OF MEASURING SIGNALING PATHWAY ACTIVITY FOR SELECTION OF THERAPEUTIC AGENTSApril 2022February 2025Allow3420NoNo
17703354Hemostasis Measurement Device Quality Control FormulationsMarch 2022October 2023Allow1800NoNo
17674400METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING, GERMLINE MISMATCH REPAIR DEFICIENCIES, LYNCH SYNDROME AND ASSESSING GERMLINE RISKS OF CANCERFebruary 2022March 2025Allow3731YesNo
17651235METHODS OF CLASSIFYING RESPONSE TO IMMUNOTHERAPY FOR CANCERFebruary 2022March 2024Allow2522NoNo
17665514PIPETTABLE REPLACEMENT FLUID FOR MIMICKING PIPETTABILITY OF TARGET FLUID AND RELATED METHODFebruary 2022October 2024Abandon3210NoNo
17588754PROTEIN SEQUENCING METHODS AND REAGENTSJanuary 2022December 2025Allow4721NoNo
17631414METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINSJanuary 2022October 2025Allow4501NoNo
17579437SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITYJanuary 2022September 2024Abandon3210NoNo
17563279AUTOANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCERDecember 2021September 2024Allow3220NoNo
17558421METHODS AND KITSDecember 2021January 2025Abandon3701NoNo
17645451METHOD FOR SCREENING PERSONALIZED INTESTINAL ENVIRONMENT-IMPROVING MATERIAL AND COMPOSITION THEREFORDecember 2021February 2025Allow3820NoNo
17557839Method and apparatus for detecting a presence of a fluorescence pattern type on an organ section by means of immunofluorescence microscopyDecember 2021September 2025Allow4531NoNo
17557988THERAPEUTIC ANTICANCER NEOEPITOPE VACCINEDecember 2021March 2024Allow2700NoNo
17621123A METHOD FOR PREDICTING RISK OF RECURRENCE FOR EARLY-STAGE COLON CANCER BY MEASURING FOCAL ADHESION KINASEDecember 2021August 2025Abandon4401NoNo
17511750METHOD FOR TRAINING AND TESTING SHORTCUT DEEP LEARNING MODEL CAPABLE OF DIAGNOSING MULTI-CANCER USING BIOMARKER GROUP-RELATED VALUE INFORMATION AND LEARNING DEVICE AND TESTING DEVICE USING THE SAMEOctober 2021September 2022Allow1111YesNo
17605730BIOMARKERS FOR PREDICTING RESISTANCE TO CANCER DRUGSOctober 2021August 2025Abandon4601NoNo
17508026GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIESOctober 2021October 2025Allow4820NoNo
17507320RAPID MEASUREMENT OF TOTAL VITAMIN D IN BLOODOctober 2021September 2024Abandon3520NoNo
17603667CALIBRATION METHODS AND COMPOSITIONS FOR BIOMOLECULE ANALYSISOctober 2021February 2026Abandon5221NoNo
17601054CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETYOctober 2021June 2025Allow4511NoNo
17486381METHODS OF MAKING TARGETED VESICLES, AND COMPOSITIONS MADE THEREBYSeptember 2021March 2026Allow5411NoNo
17598185MULTIGENE ASSAY TO ASSESS RISK OF RECURRENCE OF CANCERSeptember 2021March 2025Allow4201NoNo
17482700METHODS FOR REDUCING INTERFERENCESSeptember 2021April 2025Allow4320NoNo
17436744ANTI-BIOTIN ANTIBODY AND APPLICATION THEREOFSeptember 2021January 2023Allow1720YesNo
17465101CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYSeptember 2021January 2023Allow1630NoNo
17465096CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYSeptember 2021October 2022Allow1330YesNo
17409168METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILUREAugust 2021February 2024Allow3010NoNo
17310274LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORINGJuly 2021May 2025Abandon4511NoNo
17385508METHODS OF INHIBITING LYSINE-SPECIFIC DEMETHYLASE 1 (LSD-1)July 2021September 2023Allow2611NoNo
17378829METHODS AND KITS FOR PREDICTING PROGNOSIS OF CANCER USING SOLUBLE MORTALIN IN BLOODJuly 2021November 2024Abandon4001NoNo
17422444DEVICES AND METHODS FOR TISSUE AND CELL STAINING (II)July 2021August 2024Allow3731NoNo
17422226DNA MONOCLONAL ANTIBODIES TARGETING PD-1 FOR THE TREATMENT AND PREVENTION OF CANCERJuly 2021July 2025Allow4821NoNo
17354656CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYJune 2021September 2022Allow1420YesNo
17354653CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYJune 2021September 2022Allow1530YesNo
17297599APTAMERS AGAINST IMATINIBMay 2021December 2024Abandon4201NoNo
17296752ANTI-4-1BB ANTIBODY AND USE THEREOFMay 2021September 2024Allow3910NoNo
17309221MONOCLONAL ANTIBODIES AGAINST LORICRINMay 2021June 2025Allow5011NoNo
17290185MATERIALS AND METHODS FOR TREATING CANCERApril 2021December 2025Allow5621NoNo
17287946ANTI-CLDN18.2 ANTIBODY AND USES THEREOFApril 2021January 2026Allow5721NoNo
17229119METHODS FOR DETECTING AND/OR MEASURING ANTI-DRUG ANTIBODIES, IN PARTICULAR TREATMENT-EMERGENT ANTI-DRUG ANTIBODIESApril 2021October 2025Allow5450NoNo
17283902B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOFApril 2021June 2025Abandon5011NoNo
17223858Absolute Quantitation of Proteins and Protein Modifications by Mass Spectrometry with Multiplexed Internal StandardsApril 2021August 2025Abandon5330NoNo
17281663ANTIBODIES TARGETING EPN1March 2021April 2025Allow4911NoNo
17215923SYSTEM AND SENSOR ARRAYMarch 2021May 2022Allow1421YesNo
17188006MITOCHONDRIAL PROTEASE OMA1 AS A MARKER FOR BREAST CANCERMarch 2021January 2024Abandon3501NoNo
17272000Activation of Antigen Presenting Cells and Methods for Using the SameFebruary 2021June 2025Abandon5211NoNo
17169033KIT AND METHOD FOR DETERMINING PROSTATE CANCER MALIGNANCYFebruary 2021May 2024Abandon3920NoNo
17161783ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINSJanuary 2021February 2024Allow3711NoNo
17131328CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYDecember 2020March 2022Allow1521YesNo
17131339CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYDecember 2020March 2022Allow1521YesNo
17131326CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITYDecember 2020March 2022Allow1521YesNo
17058143NOVEL MONOCLONAL ANTIBODY HAVING ANTI-INFLAMMATORY ACTIONNovember 2020December 2024Abandon4911NoNo
17101693MEANS AND METHODS FOR DETERMINING RISK OF TYPE-1 DIABETES BY SERUM PROTEIN BIOMARKERSNovember 2020February 2024Allow3810NoNo
17055429STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN-8November 2020September 2025Allow5921NoNo
17090566METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1November 2020March 2025Abandon5221NoNo
17078417Methods of Detecting and Preventing Atopic Allergic DiseasesOctober 2020March 2025Abandon5221NoNo
17069349NOVEL ANTI-THYMIDINE KINASE ANTIBODIESOctober 2020April 2024Allow4201NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COOK, LISA V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
1
(33.3%)
Examiner Reversed
2
(66.7%)
Reversal Percentile
85.5%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
25
Allowed After Appeal Filing
3
(12.0%)
Not Allowed After Appeal Filing
22
(88.0%)
Filing Benefit Percentile
14.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COOK, LISA V - Prosecution Strategy Guide

Executive Summary

Examiner COOK, LISA V works in Art Unit 1642 and has examined 357 patent applications in our dataset. With an allowance rate of 71.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner COOK, LISA V's allowance rate of 71.4% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by COOK, LISA V receive 2.06 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COOK, LISA V is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +14.2% benefit to allowance rate for applications examined by COOK, LISA V. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.3% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.6% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 76.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.4% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.0% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.